We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Circulating Microvesicle-Based Assay Is Potential Prostate Cancer Diagnostic

By LabMedica International staff writers
Posted on 26 May 2011
A circulating microvesicle ("cMV")-based test is a potentially powerful diagnostic tool for detecting prostate cancer.

cMVs are sub-cellular membrane-bound vesicles, ranging from 30 nm to 1,500 nm in size, that are found circulating in the blood and other body fluids. More...
They are released from various cell types under both normal and pathologic conditions, including cancer. Each population of cMV expresses an array of proteins which reflects its cell-of-origin.

Carisome Technology is a versatile blood-based, highly reproducible testing technology. The technology platform identifies and characterizes cMVs, creating disease-specific, cMV-based biosignatures, which can be made up of a combination of biomarkers. The unique cMV biosignature can then be used for the diagnosis, prognosis, and measurement of therapeutic response.

The assay that enables the isolation, capture, and characterization of cMVs specific to prostate cancer was developed by Caris Life Sciences (Dallas, TX, USA). It has potential to deliver more accurate diagnoses for men with prostate cancer than current methods.

A poster highlighting the potential of the circulating microvesicle (cMV)-based prostate cancer test was presented at the American Urological Association (AUA) 2011 Annual Meeting, which was held in Washington DC (USA) from May 14-19, 2011.

Related Links:

Caris Life Sciences



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.